Last reviewed · How we verify
N1539
N1539, marketed by Baudax Bio, is a therapeutic agent with a key composition patent expiring in 2028. The drug's mechanism of action involves interacting with a specific biological target, providing a unique therapeutic effect. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | N1539 |
|---|---|
| Also known as | Intravenous meloxicam, Meloxicam IV, meloxicam |
| Sponsor | Baudax Bio |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Pharmacokinetics of N1539 in Children 2 to <17 Years of Age Following Surgery (PHASE4)
- Evaluation of N1539 Following Major Surgery (PHASE3)
- Evaluation of Preoperative N1539 in Colorectal Surgery (PHASE3)
- Evaluation of Preoperative N1539 in Total Knee Arthroplasty (PHASE3)
- Evaluation of N1539 Following Abdominoplasty Surgery (PHASE3)
- Evaluation of N1539 Following Bunionectomy Surgery (PHASE3)
- Placebo-Controlled Evaluation of N1539 Following Bunionectomy Surgery (PHASE2)
- Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- N1539 CI brief — competitive landscape report
- N1539 updates RSS · CI watch RSS
- Baudax Bio portfolio CI